Related Experiment Video

Updated: Jun 24, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Hepatitis C in Pakistan: magnitude, genotype, disease characteristics and therapeutic response

Wasim Jafri1, Amna Subhan

  • 1Department of Medicine, Aga Khan University, P.O. Box 3500, Stadium Road, Karachi - 74800, Pakistan. Wasim.jafri@aku.edu

Tropical Gastroenterology : Official Journal of the Digestive Diseases Foundation
|March 28, 2009
PubMed

Insights

Hepatitis C virus (HCV) affects 170 million globally, with Pakistan having a 2.4%-6.5% prevalence. Genotype 3 is most common and treatable, but unsafe practices drive HCV spread.

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis C virus (HCV) is a major global health concern, causing significant morbidity and mortality.
  • The virus affects 170 million people worldwide, with Pakistan experiencing a prevalence of 2.4%-6.5%.

Purpose of the Study:

  • To highlight the prevalence and transmission factors of Hepatitis C virus in Pakistan.
  • To identify the predominant HCV genotype and its response to treatment.
  • To emphasize the need for control measures against HCV spread.

Main Methods:

  • This study is a review of existing literature on Hepatitis C virus in Pakistan.
  • Data on prevalence, genotypes, transmission, and treatment response were analyzed.

Main Results:

  • Genotype 3 is the most prevalent HCV genotype in Pakistan.
  • Unsafe therapeutic injections, blood transfusions, and razor reuse are key transmission routes.
  • HCV is a leading cause of chronic liver disease and hepatocellular carcinoma in Pakistan.

Conclusions:

  • Effective control strategies are crucial to mitigate HCV transmission in Pakistan.
  • Addressing unsafe medical practices and blood safety is paramount.
  • Public health interventions are needed to reduce the burden of HCV-related liver disease.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...